AMGN and GILD Related Headlines
Go Back- Morgan Stanley tracks US drug market prescriptions for week ending July 31
- U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
- Jefferies Starts Amgen (AMGN) at Hold
- Jefferies Starts Vertex (VRTX) at Buy
- Jefferies Starts Gilead Sciences (GILD) at Buy
- Barclays launches U.S. biopharma coverage with four preferred picks
- 14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
- Trump to announce prescription drug price agreements
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
- RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
